

UNITED STATES DISTRICT COURT  
DISTRICT OF NEW JERSEY

BAUSCH HEALTH IRELAND  
LIMITED, *et al.*,

Plaintiffs,

v.

PADAGIS ISRAEL PHARMACEUTICALS  
LIMITED, *et al.*,

Defendants.

Civil Action No. 20-5426 (SRC) (CLW)  
(CONSOLIDATED)

*Document Electronically Filed*

**STIPULATION AND ORDER  
REGARDING INFRINGEMENT**

WHEREAS, in light of the Court's Claim Construction Opinion and Order (ECF No. 83), the Stipulation and Order on Supplemental Claim Constructions (ECF No. 105), and the Court's Opinion & Order dated September 21, 2022 (ECF No. 196), Plaintiffs Bausch Health Ireland Limited, Bausch Health Americas, Inc., and Bausch Health US, LLC (collectively, "Bausch" or "Plaintiffs"), and Defendants Padagis Israel Pharmaceuticals Limited and Padagis US LLC (collectively, "Padagis" or "Defendants") agree to enter into this stipulation regarding the Asserted Claims of U.S. Patent Nos. 10,251,895 and 10,426,787 to further narrow the disputed issues in the case;

WHEREAS the Court's Opinion and Order (ECF No. 196) granting Plaintiffs' motion *in limine* Nos. 1 and 3 and granting in part Plaintiffs' motion *in limine* No. 4 has the effect of precluding Padagis's infringement defense related to statistical significance;

WHEREAS, in view of the rulings specified above, Padagis agrees to enter into stipulations that both Padagis's Halobetasol and Tazarotene ANDA Product and Bausch's Duobrii® Product are covered by the asserted claims of two patents Bausch has asserted in this Action, U.S. Patent Nos. 10,251,895 and 10,426,787, subject to Padagis's right of appeal,

including appeal of infringement of the Asserted Claims of U.S. Patent Nos. 10,251,895 and 10,426,787;

NOW THEREFORE, Plaintiffs and Defendants further stipulate and agree as follows:

1. Padagis Israel Pharmaceuticals Limited has submitted Abbreviated New Drug Application No. 214626 (“Padagis’s Halobetasol and Tazarotene ANDA”) seeking approval to market a generic halobetasol and tazarotene topical lotion, 0.01%/0.045% (“Padagis’s Halobetasol and Tazarotene ANDA Product”).

2. Bausch asserts in this Action (*inter alia*) that Padagis infringed claims 3 and 6 of U.S. Patent No. 10,251,895, and claims 4, 5, and 7 of U.S. Pat. No. 10,426,787 (collectively, the “Asserted Claims of U.S. Patent Nos. 10,251,895 and 10,426,787”) under 35 U.S.C. § 271(e)(2) by the submission of Padagis’s Halobetasol and Tazarotene ANDA, and would also infringe the same claims (directly or indirectly) under 35 U.S.C. § 271(a)-(c) by making, using, offering to sell, or selling Padagis’s Halobetasol and Tazarotene ANDA Product.

3. Padagis stipulates, in light of the rulings above, that the submission of Padagis’s Halobetasol and Tazarotene ANDA to the FDA infringed each of the Asserted Claims of U.S. Patent Nos. 10,251,895 and 10,426,787.

4. Padagis stipulates that, in light of the rulings above, the manufacture, use, offer to sell, sale, and/or importation of Padagis’s Halobetasol and Tazarotene ANDA Product would infringe each of the Asserted Claims of U.S. Patent Nos. 10,251,895 and 10,426,787.

5. Padagis and Bausch stipulate that, in light of the rulings above, Bausch’s Duobrii® Product (also identified as IDP-118) embodies each of the Asserted Claims of U.S. Patent Nos. 10,251,895 and 10,426,787. For the avoidance of doubt, Bausch maintains its position that Bausch’s Duobrii® Product (also identified as IDP-118) embodies each of the Asserted Claims of U.S. Patent Nos. 10,251,895 and 10,426,787 irrespective of the rulings above.

6. The Parties stipulate that, in light of this stipulation and the Court's rulings above, neither Plaintiffs nor Defendants will call Dr. Philip Lavin or Dr. Rebecca Betensky at trial, or any other witness on the issue of infringement.

7. The parties agree that the foregoing stipulation and agreement is made without prejudice to Padagis's positions regarding the invalidity of the Asserted Claims and without prejudice of any right to appeal, including appeal of infringement of the Asserted Claims of U.S. Patent Nos. 10,251,895 and 10,426,787.

SO STIPULATED:

Dated: September 23, 2022

s/ William P. Deni, Jr.  
William P. Deni, Jr.  
J. Brugh Lower  
**GIBBONS P.C.**  
One Gateway Center  
Newark, New Jersey 07102  
Tel: (973) 596-4500  
Fax: (973) 596-0545  
wdeni@gibbonslaw.com  
jlower@gibbonslaw.com

Thomas P. Steinder (*pro hac vice*)  
April Weisbruch (*pro hac vice*)  
Christopher M. Bruno (*pro hac vice*)  
Joshua Revilla (*pro hac vice*)  
Timothy Dunker (*pro hac vice*)  
**MCDERMOTT WILL & EMERY LLP**  
500 North Capitol Street N.W.  
Washington, D.C. 20001  
Tel: (202) 756-8000

*Attorney for Plaintiffs*  
*Bausch Health Ireland Limited,*  
*Bausch Health Americas, Inc.,*  
*and Bausch Health US, LLC*

Dated: September 23, 2022

s/ Karen A. Confoy  
Karen A. Confoy  
Cali R. Spota  
**FOX ROTHSCCHILD LLP**  
Princeton Pike Corporate Center  
997 Lenox Drive  
Lawrenceville, New Jersey 08648  
Tel: (609) 896-3600  
Fax: (609) 896-1469  
kconfoy@foxrothschild.com  
cspota@foxrothschild.com

Joseph M. Reisman (*pro hac vice*)  
**KNOBBE, MARTENS, OLSON  
& BEAR, LLP**  
12790 El Camino Real  
San Diego, CA 92130  
(858) 707-4000

Bill Zimmerman (*pro hac vice*)  
**KNOBBE, MARTENS, OLSON  
& BEAR, LLP**  
1717 Pennsylvania Avenue N.W.  
Suite 900  
Washington D.C. 20006  
(202) 640-6400

Carol Pitzel Cruz (*pro hac vice*)  
**KNOBBE, MARTENS, OLSON  
& BEAR, LLP**  
925 Fourth Avenue, Suite 2500  
Seattle, WA 98104  
(206) 405-2000

*Attorneys for Defendants  
Padagis Israel Pharmaceuticals  
Limited and Padagis US LLC*

SO ORDERED this 26th day of September, 2022:

s/ Stanley R. Chesler

---

Hon. Stanley R. Chesler, U.S.D.J.